文献速递淋巴瘤造血干细胞移植与细胞治疗

大B细胞淋巴瘤真实世界治疗模式:CAR-T获批前后演变

Real-world treatment patterns of patients with large B-cell lymphoma over time and into a post-CAR T approval era.
PubMed 文献 · Blood Adv · 2026-01-01

13%的患者在1年内未启动二线治疗即死亡,30%启动二线治疗;在适合CAR-T的患者中,25%接受二线CAR-T、36%接受三线CAR-T,显示CAR-T实际使用率仍低。

要点

  • 13%患者一线治疗后1年内未启动二线治疗即死亡。
  • 适合CAR-T患者中仅25%接受二线CAR-T、36%接受三线CAR-T。
  • 需加强社区肿瘤医生与CAR-T中心早期协作以提高可及性。

核心结论

  • 尽管CAR-T具有治愈潜力,但在潜在合格患者中实际使用率仍低。
  • 许多患者在一线治疗后1年内、尚未有机会接受CAR-T前死亡。

研究设计与样本

  • 回顾性研究,基于Flatiron健康研究数据库。
  • 采用竞争风险回归模型评估启动二线治疗前死亡预测因素。

主要发现

  • 竞争风险分析中,ECOG PS评分为0/1/未知(合并)的患者中11%在一线治疗启动后12个月内、未能接受二线治疗前死亡。
  • 在判定符合且适合CAR-T的患者中,25%接受二线CAR-T治疗,36%接受三线CAR-T治疗。

临床怎么用

  • 社区肿瘤医生与CAR-T中心应早期协作,以改善CAR-T治疗可及性。
  • 需改进患者获取途径并扩大患者认知策略以提高CAR-T使用率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A significant proportion of patients with large B-cell lymphoma (LBCL) experience relapsed or refractory (R/R) disease after first-line (1L) therapy. Chimeric antigen receptor T-cell (CAR T) therapy is approved for R/R LBCL, yet real-world use remains unclear. This retrospective study evaluated treatment patterns and survival outcomes in patients potentially eligible for CAR T in the Flatiron Health Research Database. Patients diagnosed with LBCL from 2011 to 2024 who initiated 1L therapy were assessed. Predictors of mortality before the opportunity to initiate second-line (2L) therapy were evaluated using competing risk regression models. Treatment patterns among subgroups that initiated 2L and third-line (3L) therapy based timing of US Food and Drug Administration indication approvals for CAR T were evaluated and stratified by CAR T fitness using age and Eastern Cooperative Oncology Group performance status (ECOG PS) score. Among 10 016 patients who initiated 1L therapy, 13% died within 1 year without initiating 2L therapy, and 30% initiated 2L therapy. In competing risk analyses, 11% of patients with an ECOG PS score of 0/1/unknown (combined) died within 12 months of initiating 1L therapy before being able to receive 2L therapy. Among patients deemed eligible and fit for CAR T therapy, 25% received 2L CAR T therapy, and 36% received 3L CAR T therapy. Despite its curative potential, CAR T uptake remains low in potentially eligible patients, with many dying within 1 year of initiating 1L therapy and before the opportunity to receive CAR Ts. Early collaboration between the community oncologist and CAR T center, improved access, and expanded patient awareness strategies are needed to improve CAR T therapy uptake.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Perales MA, McGuirk JP, Fesen MR, et al. Real-world treatment patterns of patients with large B-cell lymphoma over time and into a post-CAR T approval era. Blood Adv. 2026. PMID: 42234934. doi:10.1182/bloodadvances.2025019064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。